MyFinsight
Home
Blog
About
Contact
Download
Download image
Net earnings (loss)
-$38,550K
(-152.19%↓ Y/Y)
Income tax expense
(benefit)
-$10,480K
(-143.66%↓ Y/Y)
Interest and other
income, net
$13,253K
(-18.21%↓ Y/Y)
Earnings (loss) before
income taxes
-$49,030K
(-150.10%↓ Y/Y)
Total other income
(expense), net
$13,253K
(-18.21%↓ Y/Y)
Product
$626,536K
(-1.75%↓ Y/Y)
Collaboration Revenue
$52,996K
Royalty License And
Other Revenue
$39,420K
(63.43%↑ Y/Y)
Operating earnings (loss)
-$62,283K
(-176.27%↓ Y/Y)
Total revenues
$718,952K
(8.63%↑ Y/Y)
Total costs and
expenses
$781,235K
(34.66%↑ Y/Y)
Selling, general and
administrative
$485,563K
(50.99%↑ Y/Y)
Research and development
$106,235K
(-2.35%↓ Y/Y)
Amortization of intangible
assets
$89,456K
(14.72%↑ Y/Y)
Cost of revenues
$74,562K
(-4.29%↓ Y/Y)
Contingent consideration
loss (gain)
$25,419K
(516.02%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)